Martin is a Medicinal and Organic Chemist, specialising in computer-aided drug design. Current projects are focussed on infectious diseases such as Dengue, West Nile and human coronaviruses. Specific molecular target classes include Flaviviral and Coronaviral protease enzymes. Martin also works on G Protein-Coupled Receptors implicated in human disease such as PAR2, C3aR and C5aR, and converting native peptide ligands into small molecule therapeutics.